OncoZenge boosts regulatory team ahead of BupiZenge study

Swedish biotech OncoZenge (Nasdaq: ONCOZ) has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies.

The company has brought in Christina Junvik through a partnership with PharmaRelations. Ms Junvik will coordinate regulatory strategy and documentation and take part in oversight of the Phase III trial.

OncoZenge said Ms Junvik, who has more than two decades of industry experience across clinical and regulatory development, including at Novartis (NOVN: VX), would play a central role in decision-making and communication with manufacturing, clinical and commercial partners.